SLDB vs. RXRX

Last updated Jul 11, 2026

SLDB (Solid Biosciences Inc.) and RXRX (Recursion Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — SLDB in Drug Manufacturers - Specialty & Generic, RXRX in Biotechnology. Over the past 5 years, SLDB returned -27.13%/yr vs -38.40%/yr for RXRX. At a 0.37 correlation, their price movements are largely independent.

Performance

SLDB vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Solid Biosciences Inc. (SLDB) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SLDB achieves a 84.75% return, which is significantly higher than RXRX's -12.96% return.

SLDB

• 1D: -6.46%
• 1M: 45.94%
• 6M: 96.98%
• YTD: 84.75%
• 1Y: 98.10%
• 3Y*: 26.32%
• 5Y*: -27.13%
• 10Y*: —

RXRX

• 1D: -5.32%
• 1M: 13.02%
• 6M: -23.61%
• YTD: -12.96%
• 1Y: -32.58%
• 3Y*: -19.32%
• 5Y*: -38.40%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

SLDB vs. RXRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
SLDB Solid Biosciences Inc.	84.75%	41.00%	-34.85%	14.13%	-79.50%	-66.15%
RXRX Recursion Pharmaceuticals, Inc.	-12.96%	-39.50%	-31.44%	27.89%	-54.99%	-42.90%

Correlation

The correlation between SLDB and RXRX is 0.46, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.46
Correlation (3Y) Calculated over the trailing 3-year period	0.42
Correlation (5Y) Calculated over the trailing 5-year period	0.38
Correlation (All Time) Calculated using the full available price history since Apr 16, 2021	0.37

Fundamentals

Market Cap SLDB : $811.82M RXRX : $1.59B
EPS SLDB : -$3.04 RXRX : -$1.12
Total Revenue (TTM) SLDB : $0.00 RXRX : $66.29M
Gross Profit (TTM) SLDB : -$853.00K RXRX : -$22.83M
EBITDA (TTM) SLDB : -$190.68M RXRX : -$505.90M

Return for Risk

SLDB vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SLDB

SLDB Risk / Return Rank: 79
SLDB Sharpe Ratio Rank: 80
SLDB Sortino Ratio Rank: 79
SLDB Omega Ratio Rank: 76
SLDB Calmar Ratio Rank: 80
SLDB Martin Ratio Rank: 79

RXRX

RXRX Risk / Return Rank: 22
RXRX Sharpe Ratio Rank: 20
RXRX Sortino Ratio Rank: 22
RXRX Omega Ratio Rank: 24
RXRX Calmar Ratio Rank: 21
RXRX Martin Ratio Rank: 24

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SLDB vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Solid Biosciences Inc. (SLDB) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	SLDB	RXRX	Difference
Sharpe ratio: Return per unit of total volatility	1.15	-0.54	+1.69
Sortino ratio: Return per unit of downside risk	1.97	-0.50	+2.47
Omega ratio: Gain probability vs. loss probability	1.23	0.95	+0.28
Calmar ratio: Return relative to maximum drawdown	2.09	-0.65	+2.74
Martin ratio: Return relative to average drawdown	5.11	-0.98	+6.09

SLDB vs. RXRX - Sharpe Ratio Comparison

The current SLDB Sharpe Ratio is 1.15, which is higher than the RXRX Sharpe Ratio of -0.54. The chart below compares the historical Sharpe Ratios of SLDB and RXRX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

SLDB vs. RXRX - Drawdown Comparison

The maximum SLDB drawdown since its inception was -99.76%, which is greater than RXRX's maximum drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for SLDB and RXRX.

Drawdown Indicators

	SLDB	RXRX	Difference
Max Drawdown Largest peak-to-trough decline	-99.76%	-93.13%	-6.63%
Max Drawdown (1Y) Largest decline over 1 year	-44.41%	-58.17%	+13.76%
Max Drawdown (3Y) Largest decline over 3 years	-82.92%	-82.09%	-0.83%
Max Drawdown (5Y) Largest decline over 5 years	-96.06%	-92.11%	-3.95%
Current Drawdown Current decline from peak	-98.66%	-91.39%	-7.27%
Average Drawdown Average peak-to-trough decline	-87.78%	-75.60%	-12.18%
Ulcer Index Depth and duration of drawdowns from previous peaks	18.12%	38.43%	-20.31%

Volatility

SLDB vs. RXRX - Volatility Comparison

Solid Biosciences Inc. (SLDB) has a higher volatility of 20.80% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 15.85%. This indicates that SLDB's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SLDB	RXRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	20.80%	15.85%	+4.95%
Volatility (6M) Calculated over the trailing 6-month period	58.64%	45.37%	+13.27%
Volatility (1Y) Calculated over the trailing 1-year period	80.55%	70.10%	+10.45%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	92.59%	93.58%	-0.99%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	108.82%	93.21%	+15.61%

Dividends

SLDB vs. RXRX - Dividend Comparison

Neither SLDB nor RXRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both SLDB and RXRX in my portfolio?

SLDB and RXRX have a correlation of 0.46, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SLDB or RXRX?

SLDB has higher volatility (20.80%) compared to RXRX (15.85%). In terms of maximum drawdown, SLDB dropped -99.76% vs RXRX's -93.13%.

Which has better risk-adjusted returns?

SLDB currently has the higher Sharpe Ratio (1.15 vs -0.54), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.